UY39604A - Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso - Google Patents
Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de usoInfo
- Publication number
- UY39604A UY39604A UY0001039604A UY39604A UY39604A UY 39604 A UY39604 A UY 39604A UY 0001039604 A UY0001039604 A UY 0001039604A UY 39604 A UY39604 A UY 39604A UY 39604 A UY39604 A UY 39604A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- cystic fibrosis
- modulators
- regulatory protein
- transmembrane conductance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Abstract
La presente invención proporciona compuestos de Fórmula (I) (I) en donde R1, R2, R3, m y n tienen cualquiera de los valores definidos en la memoria descriptiva, y sales farmacéuticamente aceptables de estos, composiciones farmacéuticas que los comprenden y métodos para tratar la fibrosis quística mediante la administración de un compuesto de la invención.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163134398P | 2021-01-06 | 2021-01-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39604A true UY39604A (es) | 2022-07-29 |
Family
ID=80349653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039604A UY39604A (es) | 2021-01-06 | 2022-01-04 | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220211692A1 (es) |
EP (1) | EP4274828A1 (es) |
JP (1) | JP2022106286A (es) |
AR (1) | AR124575A1 (es) |
TW (1) | TW202241875A (es) |
UY (1) | UY39604A (es) |
WO (1) | WO2022150174A1 (es) |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1765347A4 (en) | 2004-06-04 | 2008-10-01 | Univ California | COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE |
ME02970B (me) | 2004-06-24 | 2018-07-20 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
HUE025553T2 (en) | 2007-05-25 | 2016-02-29 | Vertex Pharma | CFTR modulators |
CL2008003651A1 (es) | 2007-12-10 | 2009-06-19 | Novartis Ag | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. |
EP2231671B1 (en) | 2007-12-13 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
KR20110074916A (ko) | 2008-10-23 | 2011-07-04 | 버텍스 파마슈티칼스 인코포레이티드 | N-(4-(7-아자비시클로[2.2.1]헵탄-7-일)-2-(트리플루오로메틸)페닐)-4-옥소-5-(트리플루오로메틸)-1,4-디히드로퀴놀린-3-카르복스아미드의 고체 형태 |
EP2382197B1 (en) | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
BR112013007907A2 (pt) | 2010-10-08 | 2016-06-14 | N30 Pharmaceuticals Inc | novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
ES2716723T3 (es) | 2011-09-20 | 2019-06-14 | Univ North Carolina Chapel Hill | Regulación de los canales de sodio por las proteínas PLUNC |
WO2014180562A1 (en) | 2013-05-07 | 2014-11-13 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis |
SG11201600891UA (en) | 2013-08-08 | 2016-03-30 | Galapagos Nv | Thieno[2,3-c]pyrans as cftr modulators |
CA2942386A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
AU2015229117A1 (en) | 2014-03-13 | 2016-09-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
SG11201703391VA (en) | 2014-10-31 | 2017-05-30 | Abbvie S À R L | Substituted chromanes and method of use |
BR112017009194A2 (pt) | 2014-10-31 | 2017-12-26 | Abbvie Sarl | tetra-hidropiranos substituídos e método de uso |
JP2018516932A (ja) | 2015-06-02 | 2018-06-28 | アッヴィ・エス・ア・エール・エル | 置換ピリジンおよび使用方法 |
US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
PL3359541T3 (pl) | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
BR112018007145A2 (pt) | 2015-10-09 | 2018-11-06 | AbbVie S.à.r.l. | ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso |
EP3448842A1 (en) | 2016-04-26 | 2019-03-06 | AbbVie S.À.R.L. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US20180133046A1 (en) | 2016-11-17 | 2018-05-17 | Osteodirit, Inc. | Custom spinal orthosis, methodology and wear compliance |
TW201831471A (zh) * | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
US10988454B2 (en) * | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
GB201801355D0 (en) | 2018-01-26 | 2018-03-14 | Enterprise Therapeutics Ltd | Compounds |
-
2021
- 2021-12-17 US US17/554,099 patent/US20220211692A1/en not_active Abandoned
- 2021-12-17 EP EP21856908.5A patent/EP4274828A1/en active Pending
- 2021-12-17 WO PCT/US2021/063983 patent/WO2022150174A1/en unknown
- 2021-12-21 JP JP2021206763A patent/JP2022106286A/ja active Pending
-
2022
- 2022-01-04 UY UY0001039604A patent/UY39604A/es unknown
- 2022-01-05 AR ARP220100015A patent/AR124575A1/es unknown
- 2022-01-06 TW TW111100598A patent/TW202241875A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20220211692A1 (en) | 2022-07-07 |
JP2022106286A (ja) | 2022-07-19 |
WO2022150174A1 (en) | 2022-07-14 |
TW202241875A (zh) | 2022-11-01 |
EP4274828A1 (en) | 2023-11-15 |
AR124575A1 (es) | 2023-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19048759A (es) | Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, y proceso para producir el modulador | |
UY37617A (es) | Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo | |
ECSP21077043A (es) | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
DOP2023000016A (es) | Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos | |
CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
ECSP22052564A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
CO2022002634A2 (es) | Formas cristalinas de moduladores del cftr | |
PA8616201A1 (es) | Composiciones farmaceuticas de liberacion sostenida | |
DOP2019000070A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos | |
CO2022004723A2 (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
CO2022004698A2 (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
CO2022017622A2 (es) | Inhibidores de quinasa nek7 | |
CO2022019131A2 (es) | Inhibidores de la quinasa nek7 | |
CO2019002616A2 (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos | |
PE20210550A1 (es) | Compuestos de 4-metildihidropirimidinona y su uso farmaceutico | |
UY38006A (es) | Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones | |
CO2023014204A2 (es) | Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) | |
UY39604A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
UY39603A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
TN2018000175A1 (en) | Indane derivatives as mglur7 modulators | |
CL2023000926A1 (es) | Inhibidores alostéricos de akt para su uso en el tratamiento de telangiectasia hemorrágica hereditaria | |
EA202190707A1 (ru) | Ингибиторы о-гликопротеин-2-ацетамидо-2-деокси-3-d-глюкопиранозидазы | |
AR124430A1 (es) | Inhibidores de arginasa y métodos de uso de ellos | |
UY27848A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos, y metodos para su uso. |